Eli Lilly has reported increased net income of 32 percent in the 2010 third quarter, compared with the previous years third quarter.

Spectranetics has reported widening net losses among its financial results for the 2010 third quarter, which ended Sept. 30, compared with the 2009 third quarter.

Compared with clopidogrel, new P2Y12 inhibitors, such as prasugrel and ticagrelor, better decrease mortality after PCI and are particularly favorable for STEMI patients, according to a meta-analysis in the November issue of the Journal of the American College of Cardiology.

Carriers of the CYP2C19 loss-of-function allele are at an increased risk for a major adverse cardiovascular event, and it is estimated that one in three of these patients do not receive ideal protection from ischemic events when treated with clopidogrel for PCI, according to a meta-analysis published in the Oct. 27 issue of the Journal of the American Medical Association.

Integrating drug-eluting stents (DES) into clinical practice has been associated with more favorable outcomes, decreased thrombotic event rates and changes in practice approach, according to the results of the EVENT registry published in the October issue of the American Heart Journal.

The Harvard Clinical Research Institute (HCRI) has expanded its DAPT study, a four-year clinical trial that will investigate the effectiveness of dual-antiplatelet therapy (DAPT) to reduce blood clots following drug-eluting stent implantations, to Australia and New Zealand.

Abbott experienced a double-digit drop in net earnings for the 2010 third quarter, which ended Sept. 30, compared with the year-over-year earnings, despite an increase in sales, due to acquisition and product recall charges.

Edwards Lifesciences, a developer of heart valves and hemodynamic monitoring, has reported an increase in net sales, but decrease in net income, due to greater spending in the third quarter of 2010, which ended Sept. 30.